Misaligned incentives
Innovators expect adoption; clinics expect a finished, validated product. Both lose in the gap.
Reproductive Health Research Institute
Rigorous Science.
Rigorous Science.
Real-World Impact.
An independent, decentralized network that validates new reproductive-health technology in real clinics — testing whether it actually works at scale, holds up economically, and improves care — so only innovation that earns it reaches patients.
01 — Why now
The path from lab to clinic is broken.
The field is producing real breakthroughs — AI embryo assessment, microfluidics, genomics. Most of it stalls before it ever reaches a patient.
No shared standard
Nothing independent validates a technology before market entry, so marketing outruns the evidence.
Clinics carry the risk
Good ideas die from adoption friction while mediocre ones survive on a sales deck.
Start-ups spend scarce capital paying clinics to trial products that arrive dead on launch. Clinics absorb the risk. Patients get inconsistent care with no clear quality signal.
02 — What RHRI is
Not a regulator, a lab, or a consultancy. Independent validation infrastructure — a network of clinics where technology is tested under real conditions, against one shared standard, and the results are published.
What we are not
- — A regulatory body
- — A single research lab
- — A commercial consultancy
- — A gatekeeper
03 — Method
The Four-Pillar Framework.
Every technology is assessed on four dimensions at once. Most evaluations test only the first. We test all four.
01
Replicability
Do results hold across operators, labs, and geographies?
Evaluated for- Intra-operator consistency
- Inter-operator validation
- Protocol & QC clarity
02
Scalability
Does it work at clinic volume and across skill levels?
Evaluated for- Function at real volume
- Tolerance to skill spread
- Scale vs. consistency
03
Sustainability
Do performance and economics hold as volume grows?
Evaluated for- Unit economics at scale
- Operational load
- Viability without strain
04
Patient Value
The only measure that ultimately counts.
Evaluated for- Lower cost, better outcomes
- Shorter time-to-baby
- Wider access
04 — Process
From prototype to practice.
A clear path through the network. Durations are typical, not guaranteed.
STEP 01
Review
Assess the technology, its stage, and what validation must prove.
2–4 WKS
STEP 02
Protocol
Design the study, define endpoints, match to clinics.
4–6 WKS
STEP 03
Validation
Tested across clinics, geographies, and operators.
3–6 MOS
STEP 04
Evidence
Measured against the four pillars — and published.
4–8 WKS
STEP 05
Implementation
SOPs, training, and rollout for what earns it.
ONGOING
05 — Who we serve
One standard. Four channels.
The same evidence means something different to each side of the network.
01
For innovators
A path that earns trust
Credible, real-world validation clinics trust — a faster, lower-cost route from prototype to adoption than buying trials one clinic at a time.
02
For clinics
Proven before you adopt
First access to technology that's actually been proven, with the protocols and support to adopt it — and far less risk.
03
For patients
The reason the standard exists
RHRI-validated means proven to improve outcomes, reduce cost, or widen access in the real world.
04
For funders
Investment that pays off
Infrastructure that makes innovation investment pay off — it grows the market, speeds translation, and separates signal from noise.
06 — Areas of innovation
Four verticals, one framework.
Every category runs through the same four pillars.
Software
AI and digital tools across the workflow: embryo assessment, follicle counting, decision support, predictive analytics.
Hardware
Devices that add precision and consistency: robotics, microfluidics, imaging, cryostorage, environmental monitoring.
Process
Re-engineering how care is delivered: lab workflow, routing, protocol integration, quality systems.
Biotech
Anything needing clinical evidence: culture media, supplements, genetic testing (PGT), biomarkers, novel culture systems.
07 — Operating model
Independence is the product.
No single headquarters. Talent and partners are distributed; pilots run where conditions are best.
Transparent funding, diverse governance, and published methodology keep the standard honest. Without independence, validation is worthless.
- 01 Evidence over enthusiasm.
- 02 Collaboration over competition.
- 03 Impact over publications.
- 04 Transparency by default.
- 05 Pragmatism over perfection.
08 — Direction
Three years out.
Foundation, then network, then standard.
2026
Foundation
Stand it up
Establish governance and the founding team. Build the validation protocols. Run the first studies and publish the methodology.
2027
Network
Grow the network
Expand the partner-clinic network. Launch membership and the validation registry. Reach sustainability.
2028
Standard
Become the standard
"RHRI-validated" becomes a recognized mark of quality. Influence guidelines; launch education and certification.
09 — Team
Science, medicine, operations.
DM
Daniel Madero
Founder & Director
Fertility executive focused on scaling clinics and building operating models across the Americas and Europe. Former CEO of Fertilidad Integral; senior advisor to RHEA and GenPrime.
CH
Cynthia Hudson
Clinical Strategy
SVP of Clinics at TMRW Life Sciences. Embryologist and medical technologist with 20+ years in reproductive medicine. Founder of NOVA Genomics; owner of Perch Fertility, New Jersey.
FA
Felicitas Azpiroz
Research & Science
Reproductive scientist at the Universitat Autònoma de Barcelona (UAB), working within the Eugin Group research ecosystem — bridging rigorous lab science and clinically relevant questions.
Advisory board and partner network are in formation, and shown as such — never invented.
Get involved
This is the foundation.
This is the foundation.
Now we build.
Innovator, clinic, researcher, or funder — if you want validation to mean something, let's talk.